Transthyretin-mediated protein and peptide oligomerization for enhanced target clustering

Daniel Yoo1, Kenneth W Walker1

  • 1Amgen Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, U.S.A.

Insights

Researchers developed a novel drug delivery platform using transthyretin (TTR) to enhance anti-tumor immune responses. This TTR-based system effectively clusters targets, showing promise for new cancer therapies and infectious disease research.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Cancer therapies like immune checkpoint inhibitors have shown success.
  • Targeting tumor necrosis factor (TNF) receptors aims to boost anti-tumor immunity but requires receptor clustering.
  • Existing methods for receptor clustering can be complex and challenging.

Purpose of the Study:

  • To present transthyretin (TTR) as a drug delivery platform for cross-linking independent target clustering.
  • To demonstrate the versatility and stability of TTR for creating multimeric antibody fusions.
  • To evaluate the therapeutic potential of TTR-based fusions in cancer models.

Main Methods:

  • Utilized transthyretin (TTR), a stable serum protein tetramer, as a fusion platform.
  • Engineered antibody or Fab fusions targeting TRAILR2.
  • Assessed cytotoxic activity of TTR fusions in vitro and in vivo using colorectal xenograft models.

Main Results:

  • Transthyretin (TTR) demonstrated a versatile and stable platform for generating multimeric antibody fusions.
  • TTR-TfR2 antibody/Fab fusions exhibited robust cytotoxic activity against cancer cells.
  • Effective in vitro and in vivo anti-tumor activity was observed in colorectal cancer models.

Conclusions:

  • Transthyretin (TTR) is a highly versatile and stable therapeutic fusion platform.
  • TTR enables enhanced target clustering, crucial for TNF receptor-based therapies.
  • This platform has broad applications in oncology and infectious disease research.

Related Concept Videos

Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
9.2K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.9K
Protein Transport to the Thylakoids01:22

Protein Transport to the Thylakoids

Thylakoids are membrane-bound sac-like structures within the chloroplast that serve as sites for photosynthesis. Thylakoid lumen contains many electron transport proteins and is enclosed by a thylakoid membrane rich in the light-harvesting complex. Proteins targeted to the thylakoids are transported as precursors and are sorted by the general TOC/TIC import pathway. Once the precursor reaches the stroma, stromal processing peptidases remove their transit signal and expose thylakoid signal...
2.5K
Export of Misfolded Proteins out of the ER01:32

Export of Misfolded Proteins out of the ER

After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
4.4K
Tail-anchoring of Proteins in the ER Membrane01:45

Tail-anchoring of Proteins in the ER Membrane

Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.4K
Protein Folding01:25

Protein Folding

Proteins are chains of amino acids linked together by peptide bonds. Upon synthesis, a protein folds into a three-dimensional conformation, critical to its biological function. Interactions between its constituent amino acids guide protein folding, and hence the protein structure is primarily dependent on its amino acid sequence.
Protein Structure Is Critical to Its Biological Function
Proteins perform a wide range of biological functions such as catalyzing chemical reactions, providing...
9.8K